cagrilintide and semaglutide 2.4mg Efficacy safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study Cagrilintide + Semaglutide Blend |

Cortical evolution 2015: discussion of neural progenitor cell nomenclature

Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions

Hartz AMS, Zhong Y, Shen AN, Abner EL, Bauer B

Monthly open topic releases Monthly open topic releases

Xu XF et al (2018) Elevating integrin-linked kinase expression has rescued hippocampal neurogenesis and memory deficits in an AD animal model